Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.

about

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.

Item

http://www.wikidata.org/entity/Q40089989

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Combination of sofosbuvir and ...... s on maintenance hemodialysis.

@en

type

Item

label

Combination of sofosbuvir and ...... s on maintenance hemodialysis.

@en

prefLabel

Combination of sofosbuvir and ...... s on maintenance hemodialysis.

@en

P1476

Combination of sofosbuvir and ...... ts on maintenance hemodialysis

@en

P2093

Dusan Merta

http://www.w3.org/2001/XMLSchema#string

Jan Sperl

http://www.w3.org/2001/XMLSchema#string

Julius Spicak

http://www.w3.org/2001/XMLSchema#string

Monika Tothova

http://www.w3.org/2001/XMLSchema#string

Sona Frankova

http://www.w3.org/2001/XMLSchema#string

P2860

Sofosbuvir for previously untreated chronic hepatitis C infection

Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection

Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population.

Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.

The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies.

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

Hepatitis C virus infection in end-stage renal disease and kidney transplantation.

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.

P304

733-738

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S133983

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Miluše Kreidlová

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28790832

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

P932

5488764

http://www.w3.org/2001/XMLSchema#string